Angerer, S. von and Seidl, E. and Mannschreck, A. and Angerer, E. von and Wiegrebe, Wolfgang (1994) Dibenzo[a,f]quinolizines: syntheses and cytostatic activity in estrogen-sensitive tumor cells. Anti-cancer drug design 9 (1), pp. 25-40.
| PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader 1842Kb |
Abstract
A number of methoxy-substituted 7,11b,12,13-tetrahydro-6H-dibenzo-[a,f]quinolizines with short alkyl groups in position 6 or 12 were synthesized by the Bischler-Napieralski reaction using the appropriate starting material followed by a second ring closure reaction involving a base-generated benzyne intermediate. The methoxy functions in positions 2 or 3 and 9 were cleaved with BBr3 and the free hydroxy groups converted into the acetates. The enantiomers of two of these derivatives were separated by liquid chromatography on triacetylcellulose. Compounds with alkyl substituents bind strongly to the estrogen receptor except those with a cis-orientation at the central ring connection. The RBA values ranged from 2.2-10.8 (17 beta-estradiol: RBA = 100). There was no major difference in binding between the (+) and (-)-enantiomers. The 3,9-diacetoxy-6-alkyl derivatives also showed binding affinity for the progesterone receptor (RBA: 1.2-3.1). The 2,9-diacetoxydibenzoquinolizines trans-61 and -6m with ethyl and propyl respectively in position 12 strongly inhibited the growth of hormone-sensitive MCF-7 breast cancer cells at concentrations of 10(-6) M and higher but were inactive in hormone-independent MDA-MB 231 breast cancer cells. Preliminary tests with hormone-dependent MXT mouse mammary tumors as model showed that these compounds have also antineoplastic activity in vivo. Derivative trans-61 at a dose of 20 mg/kg body weight, administered 3 times/week, inhibited the growth of these tumors by 78% (tamoxifen: 76% inhibition). Studies on the estrogenic and antiestrogenic properties of these agents in mice revealed that they are mixed agonists/antagonists with strong antiestrogenic activity at low doses but significant estrogenic effects at higher doses.
| Item Type: | Article | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Institutions: | Chemistry and Pharmacy > Institut für Organische Chemie > Lehrstuhl Prof. Dr. Oliver Reiser Chemistry and Pharmacy > Institute of Pharmacy > Pharmaceutical/Medicinal Chemistry II (Prof. Buschauer) | ||||||||||||||||||||||||||
| Projects: | SFB 234 | ||||||||||||||||||||||||||
| Identification Number: |
| ||||||||||||||||||||||||||
| Classification: |
| ||||||||||||||||||||||||||
| Subjects: | 500 Science > 570 Life sciences 500 Science > 540 Chemistry & allied sciences 600 Technology > 610 Medical sciences Medicine | ||||||||||||||||||||||||||
| Status: | Published | ||||||||||||||||||||||||||
| Refereed: | Yes, this version has been refereed | ||||||||||||||||||||||||||
| Created at the University of Regensburg: | Yes | ||||||||||||||||||||||||||
| Owner: | Prof. Armin Buschauer | ||||||||||||||||||||||||||
| Deposited On: | 10 Dec 2008 17:33 | ||||||||||||||||||||||||||
| Last Modified: | 20 Jul 2011 23:22 | ||||||||||||||||||||||||||
| Item ID: | 4766 |
- ASCII Citation
- BibTeX
- Dublin Core
- EndNote
- HTML Citation
- METS
- OAI-ORE Resource Map (Atom Format)
- OAI-ORE Resource Map (RDF Format)
- RDF+N-Triples
- RDF+N3
- RDF+XML
- Refer
- Reference Manager
- Simple Metadata
- XML
- xMetaDissPlus
Literature of the same author
at PubMed
Bookmark
Deutsch
in this repository
Citeulike
Connotea
Del.icio.us
Digg
Facebook